Specialty trend reached $62.25 PMPM (+11.1%), largely from utilization growth in oncology, immunology, and dermatology; ...
The therapies are incredible, says Will Shrank, M.D. They can “totally transform the lives of those who can benefit.” But ...
Self-insured employers and other payers are the startup's customers, but Aradigm CEO and co-founder Will Shrank says the ...
After step-up dosing, treatment with bispecific antibodies does not require the use of steroids, Adams noted, so patients are ...
Financial hardship correlated strongly with nonadherence, with 37.3% of nonadherent participants unable to get by financially ...
Cross-sectional secondary analyses used SF-36 pain interference responses and medical-record diagnoses to operationalize ...
Levitt said KFF polling suggests patient frustration with prior authorization remains widespread across employer-sponsored ...
Will Shrank, M.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is leading a startup ...
Politico and The Washington Post report Makary will resign Tuesday, ending a turbulent 13-month period overseeing drug, ...
With the January 1, 2027 deadline looming, there remains a disconnect between early-stage momentum and execution maturity. On ...
Machine-learning aging clocks built from proteins, metabolites, and imaging estimated organ-specific biological aging, enabling cross-validation of sleep associations across multi-omics layers. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results